BLT.AX says CEO and Managing Director Dr Peter French Resigned, page-76

Yes, but cohort five can still continue even if cohort four does not prove efficacious.

Primary Outcome Measures:

• The primary objective is to assess the safety and tolerability of single escalating doses of TT-034 administered IV as a single infusion to subjects with CHC. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

• To assess the activity of TT-034 on the viral load of subjects with CHC receiving single escalating doses of TT-034 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Other Outcome Measures:

• To determine the maximum tolerable dose or the optimal efficacy dose (whichever comes first) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• To determine the viral load [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• To assess the presence of viral escape mutants in subjects with detectable viral load after receiving TT-034 [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• To monitor TT-034 vector DNA levels and shRNA expression in the target organ (liver) after dosing with TT-034 [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  
• To monitor TT-034 vector DNA levels and shRNA expression peripherally (in blood) after dosing with TT-034 [ Time Frame: 6 months ] [ Designated as safety issue: No ]

https://clinicaltrials.gov/ct2/show/NCT01899092?term=tacere&rank=2